8-K: Akebia Therapeutics Announces $50 Million Public Offering of Common Stock

Akebia Therapeutics has priced its underwritten public offering of 25,000,000 shares of common stock at $2.00 per share, expecting gross proceeds of $50 million.

Summary

• Akebia Therapeutics has announced the pricing of a public offering of 25,000,000 shares of its common stock at a price of $2.00 per share.
• The gross proceeds from the offering are expected to be $50.0 million before deducting underwriting discounts, commissions, and other offering expenses.
• The underwriters have been granted a 30-day option to purchase up to 3,750,000 additional shares of common stock.
• The offering is expected to close on March 21, 2025, contingent upon customary closing conditions.
• Leerink Partners and Piper Sandler & Co. are serving as joint bookrunning managers for the offering.
• BTIG, LLC is acting as lead manager, and H.C. Wainwright & Co. is acting as co-manager.
• Akebia believes that it is financed to achieve profitability based on its current operating plan.
• This estimate is based on assumptions that may prove to be wrong, and the Company may never achieve profitability.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company is raising capital, which is generally a positive step for growth, but there are inherent risks and uncertainties associated with the offering and the company's future profitability.

Positives

• The public offering is expected to generate $50 million in gross proceeds for Akebia Therapeutics.
• The company has the potential to raise additional capital if the underwriters exercise their option to purchase additional shares.
• Akebia believes that it is financed to achieve profitability based on its current operating plan.

Negatives

• The offering price of $2.00 per share may be perceived negatively if it represents a discount to the current market price.
• The company acknowledges that its estimate to achieve profitability is based on assumptions that may prove to be wrong, and the Company may never achieve profitability.

Risks

• Market conditions could affect the timing, terms, and conditions of the offering.
• There is no assurance that Akebia will be able to complete the offering on the anticipated terms, or at all.
• The company's ability to achieve profitability is uncertain and depends on various assumptions.

Future Outlook

Akebia anticipates closing the offering on March 21, 2025, subject to customary conditions, and believes it is financed to achieve profitability based on its current operating plan, although this is not guaranteed.

Management Comments

• Akebia is a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease.

Industry Context

This offering reflects ongoing capital-raising activities within the biopharmaceutical industry, where companies often seek funding to support research, development, and commercialization efforts.

Comparison to Industry Standards

• Comparable companies such as Keryx Biopharmaceuticals (acquired by Akebia) and FibroGen have also focused on kidney disease treatments.
• The success of Akebia's offering and its future performance will be benchmarked against these and other peers in the nephrology space.
• The offering size and terms are within the typical range for similar companies at Akebia's stage of development.

Stakeholder Impact

• Shareholders will experience dilution as a result of the new share issuance.
• The capital raise could enable Akebia to further its research and development efforts, potentially benefiting patients with kidney disease.
• Employees may benefit from the increased financial stability of the company.

Next Steps

• The offering is expected to close on March 21, 2025, subject to customary closing conditions.
• Akebia will file a final prospectus supplement with the SEC.
• The company will use the proceeds from the offering for general corporate purposes.

Key Dates

Keywords

public offering, common stock, Akebia Therapeutics, biopharmaceutical, kidney disease, capital raise, underwriting